AmBisome
Drug
Gilead Sciences Inc
Total Payments
$177,216
Transactions
200
Doctors
98
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $11,179 | 69 | 40 |
| 2023 | $108,139 | 58 | 46 |
| 2022 | $19,974 | 17 | 10 |
| 2021 | $1,050 | 1 | 1 |
| 2019 | $3,129 | 8 | 1 |
| 2018 | $2,249 | 6 | 3 |
| 2017 | $31,495 | 41 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $106,188 | 2 | 59.9% |
| Consulting Fee | $53,443 | 14 | 30.2% |
| Travel and Lodging | $7,596 | 34 | 4.3% |
| Space rental or facility fees (teaching hospital only) | $4,245 | 3 | 2.4% |
| Food and Beverage | $4,189 | 144 | 2.4% |
| Education | $1,555 | 3 | 0.9% |
Payments by Type
Research
$106,188
2 transactions
General
$71,028
198 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Cryptococcal Infections in Non -HIV Infected Hosts: A Prospective International Study (MSG-11) | Gilead Sciences, Inc. | $100,000 | 0 |
| Post influenza aspergillosis and the effect of a liposomal amphotericin B and oseltamivir in a corticosteroid-immunosuppressed murine model of influenza | Gilead Sciences, Inc. | $6,188 | 0 |
Top Doctors Receiving Payments for AmBisome
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New Orleans, LA | $110,433 | 5 |
| , M.D | Infectious Disease | Houston, TX | $17,661 | 11 |
| Peter Pappas | Infectious Disease | Birmingham, AL | $7,918 | 6 |
| , M.D | Infectious Disease | Miami, FL | $6,690 | 2 |
| , M.D | Pediatrics | Durham, NC | $6,296 | 14 |
| , M.D | General Acute Care Hospital | Pittsburgh, PA | $5,845 | 8 |
| , M.D | Infectious Disease | New York, NY | $5,098 | 8 |
| , MD | Internal Medicine | San Antonio, TX | $4,468 | 6 |
| , MD | Infectious Disease | Pittsburgh, PA | $3,230 | 1 |
| Michail Lionakis | Infectious Disease | Washington, DC | $3,129 | 8 |
| , MD | Infectious Disease | Boston, MA | $2,000 | 1 |
| , M.D | Infectious Disease | Houston, TX | $1,050 | 1 |
| , MD | Vascular Surgery | Worcester, MA | $209.09 | 4 |
| , M.D., FCCP | Pulmonary Disease | Metairie, LA | $192.01 | 3 |
| , FNP-BC | Registered Nurse | Sacramento, CA | $185.38 | 7 |
| , M.D | Infectious Disease | Roseville, CA | $165.53 | 6 |
| , MD | General Practice | San Juan, PR | $154.86 | 4 |
| , MD | Pulmonary Disease | Roseville, CA | $137.15 | 5 |
| , M.D | Infectious Disease | Roseville, CA | $136.75 | 5 |
| , M.D | Critical Care Medicine | Roseville, CA | $124.51 | 5 |
| , MD | Infectious Disease | Boston, MA | $81.51 | 1 |
| , MD | Internal Medicine | Saint Paul, MN | $80.26 | 1 |
| , APRN | Family | Austin, TX | $76.43 | 3 |
| , M.D | Internal Medicine | Baytown, TX | $70.52 | 1 |
| , PA-C | Physician Assistant | Roseville, CA | $61.03 | 2 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $139,402
- Gilead Sciences Inc $31,495
- Astellas Pharma US Inc $6,319
Product Information
- Type Drug
- Total Payments $177,216
- Total Doctors 98
- Transactions 200
About AmBisome
AmBisome is a drug associated with $177,216 in payments to 98 healthcare providers, recorded across 200 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $11,179 was paid across 69 transactions to 40 doctors.
The most common payment nature for AmBisome is "Unspecified" ($106,188, 59.9% of total).
AmBisome is associated with 2 research studies, including "Cryptococcal Infections in Non -HIV Infected Hosts: A Prospective International Study (MSG-11)" ($100,000).